Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting ANKRD11 Reverses Hepatitis B Virus-Specific CD8 Positive T Lymphocyte Cell Dysfunction and Tolerance

NCT07777250 is registered in ClinicalTrials.gov with Beijing Municipal Administration of Hospitals as lead sponsor.

NCT NCT07777250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07777250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting ANKRD11 Reverses Hepatitis B Virus-Specific CD8 Positive T Lymphocyte Cell Dysfunction and Tolerance
Lead sponsor
Beijing Municipal Administration of Hospitals
Phase
Observational
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
August 31, 2028
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b